01 — At a Glance
India’s Most Expensive Hospital. The Stock Too.
- 52-Week High / Low₹1,314 / ₹934
- Q3 FY26 Revenue₹2,068 Cr
- Q3 FY26 PAT (reported)₹301 Cr
- Q3 FY26 EPS₹3.09
- TTM EPS₹14.59
- Book Value₹103
- Price to Book10.1x
- Debt / Equity0.33x
- Occupancy (Q3 FY26)74%
- ARPOB (Q3 FY26)₹77,900
One-Line Verdict: Max Healthcare delivered 21 consecutive quarters of YoY growth, posted ₹2,068 Cr quarterly revenue (+10.7% YoY), but PAT took a -17.2% QoQ hit due to an exceptional item (Code on Wages + merger stamp duty), a CGHS chemo-drug pricing fiasco, and management’s candid admission of “excessive unanticipated seasonal softness.” The 3-month return sits at -5.05%. The market cap still calmly idles at ₹1.01 lakh crore. These two facts need a mediator.
02 — Introduction
Premium Hospitals. Premium Margins. Premium Valuation. Premium Headaches.
Welcome to Max Healthcare — India’s largest hospital chain by market cap, second largest by revenue and EBITDA, and quite possibly the only company that can blame a dengue season for a bad quarter and have analysts nod approvingly on the concall.
The Delhi-NCR powerhouse operates 22 hospitals and medical centres across North India with a network of ~5,200 beds. It performs 14,800 oncology surgeries and ~48,000 cardiac procedures a year. It partners with Boston University, Imperial College London, and IIT Bombay on research. It has 3,000 published research papers. And somehow, it still found itself in a bureaucratic tiff with the government over chemotherapy drug pricing at ₹70 when its purchase cost was ₹80. Government math is special.
Q3 FY26 (Oct–Dec 2025) was the 21st consecutive quarter of year-on-year growth. But growth quality took a hit — a temporary shift toward lower-margin institutional patients, GST rate changes, pre-commissioning expenses, and a vector-borne disease season so bad (or good, depending on your bed occupancy preferences) that management specifically said rains continued into winter and there was “really no stagnation of water.” So no dengue. No dengue means fewer emergency admissions. Welcome to a business where clear skies hurt your P&L.
Concall Gem (Feb 2026): Management on the seasonal miss — “excessive unanticipated seasonal softness.” Twelve words that explain a ₹253 Cr QoQ PAT drop without once blaming the company. Respect the craft.
03 — Business Model: WTF Do They Even Do?
They Fix You. Then Bill You. Repeat 5,200 Times a Day.
The business model is elegantly brutal. You get sick (or someone in your family does). You live in North India. Max Healthcare is very likely where you go, especially if you’ve got insurance or employer coverage and prefer not to make peace with the universe before a cardiac catheterisation.
Max runs 22 hospitals and medical centres in Delhi-NCR, Mumbai, Lucknow, Nagpur, Mohali, Bathinda, and Dehradun. Delhi-NCR alone contributes 55%+ of revenues — a concentration that is simultaneously their biggest strength (ARPOB leadership, surgical mix, international medical tourism) and their most cited credit risk (one bad regulation and the entire P&L gets a CGHS-shaped bruise).
Revenue comes from inpatients paying cash, third-party administrators (TPAs), corporates, institutions (government, PSU — low margin, used to fill beds), and international patients (~9% of hospital revenue, growing at 14% YoY). The adjacency businesses — Max@Home (₹68 Cr revenue, +23% YoY) and Max Lab (₹47 Cr, +13% YoY) — are small but scaling. And then there’s the big growth engine: beds. Lots of them, being added aggressively, with a stated plan to reach ~13,500 beds over time from today’s ~5,200.
Beds (Network)~5,200as of Jun 2025
ARPOB (Q3 FY26)₹77,900+3% YoY
Occupancy74%Q3 FY26
Int’l Revenue₹230 Cr9% of hosp. rev.
Expansion Obsession: Max plans to add 4,800 beds in the next 3–4 years and a further 3,500 beds by FY30. The capex pipeline is ₹2,100–2,200 Cr annually. Their balance sheet is doing the intellectual equivalent of deep breathing before a marathon. Debt has risen from ₹913 Cr in FY22 to ₹3,275 Cr in Sep 2025. Management says ROCE over per-bed metrics. The bond market gave them a CARE AA+ for doing so. Fair.
💬 Have you ever been admitted to a Max Hospital? Did your ARPOB help their quarterly numbers? Leave a comment!
04 — Financials Overview
Q3 FY26: The Numbers Behind the Narrative
Result type: Quarterly Results | Q3 FY26 EPS: ₹3.09 | Annualised EPS (Avg of Q1+Q2+Q3 × 4) = Avg(₹3.17+₹5.05+₹3.09)/3 × 4 = ₹15.08 | TTM EPS: ₹14.59
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 2,068 | 1,868 | 2,135 | +10.7% | -3.1% |
| Operating Profit | 538 | 499 | 575 | +7.8% | -6.4% |
| OPM % | 26% | 27% | 27% | -100 bps | -100 bps |
| PAT | 301 | 239 | 491 | +25.9% | -38.7% |
| EPS (₹) | 3.09 | 2.46 | 5.05 | +25.6% | -38.8% |
P/E Recalculated: TTM EPS ₹14.59 ÷ CMP ₹1,042 = P/E 71.4x (screener shows 69.5x — TTM calculation varies slightly based on timing). Industry median P/E is 43.4x. Max trades at a ~60% premium to sector median. The Q2 FY26 PAT of ₹491 Cr included a deferred tax reversal, creating an inflated base. Q3’s ₹301 Cr PAT includes ₹55 Cr exceptional items (Code on Wages provision + stamp duty on subsidiary merger). Adjust for exceptionals, and the underlying PAT trajectory is less dramatic. But 25.9% YoY PAT growth on a clean basis? That’s the actual story.
05 — Valuation: Fair Value Range
What Is This Company Actually Worth?
Join 10,000+ investors who read this every week.
